Risk of Failure to Achieve Medium-Term Management Plan Measures
First written in FY2016. 2 of 5 entries say "Softened", first in FY2017. Latest entry: FY2022.
Medical System Network moved to the "Worse" side of this theme in 2017, 5 years before the typical company in this theme (2022).
The whole theme swung hardest in 2025: 11 of 19 companies on the "Worse" side.
12 other companies' latest entry also says "Reframed".
- FY2022ReframedAnnual report
「The Group has formulated the Sixth Medium-Term Management Plan covering the four years from April 2022 through the fiscal year ending March 2026. The plan sets management targets for the final year, the fiscal year ending March 2026, of consolidated revenue of ¥140.0 billion, consolidated operating profit of ¥6.5 billion, consolidated EBITDA of ¥10.0 billion, an equity ratio of 30%, 12,000 pharmaceutical network members and 550 community pharmacy stores.」
The risk focus changed from the risk of failing to meet the targets of the Fifth Medium-Term Management Plan to the risk concerning the achievability of the Sixth Medium-Term Management Plan's targets for the fiscal year ending March 2026. - FY2021SoftenedAnnual report
「The Group had set management targets for the final year, the fiscal year ending March 2022, of 5,000 pharmaceutical network members, consolidated revenue of ¥120.0 billion, consolidated operating profit of ¥5.0 billion, consolidated EBITDA of ¥7.5 billion and an equity ratio of at least 30%. However, due to the impact of COVID-19 and other factors, its consolidated earnings forecasts for the fiscal year ending March 2022 are revenue of ¥105.7 billion, operating profit of ¥3.5 billion and EBITDA of ¥6.5 billion.」
Due to the impact of COVID-19 and other factors, the earnings forecasts for the fiscal year ending March 2022 were lowered from the initial Fifth Medium-Term Management Plan targets for revenue, operating profit and EBITDA. - FY2018ReframedAnnual report
「The Group has formulated the Fifth Medium-Term Management Plan covering the four years from April 2018 through the fiscal year ending March 2022.」
The risk focus changed from the risk of failing to meet the targets of the Fourth Medium-Term Management Plan to the risk concerning the achievability of the Fifth Medium-Term Management Plan's targets for membership, revenue, profit, EBITDA and the equity ratio. - FY2017SoftenedAnnual report
「The plan set consolidated targets for the fiscal year ended March 2018 of revenue of at least ¥105.0 billion, an ordinary profit margin of at least 3.6%, at least 2,200 pharmaceutical network members and at least 500 community pharmacy stores. However, the plan for the fiscal year ended March 2018 fell short of some of these targets, with revenue of ¥95.0 billion, an ordinary profit margin of 3.2%, 2,200 pharmaceutical network members and 407 stores.」
For the fiscal year ended March 2018, the targets for revenue, ordinary profit margin and the number of stores were lowered from the initial targets. The membership target was maintained at 2,200. - FY2016First statedAnnual report
「The Group may be unable to achieve its medium-term management plan if the expansion in the number of pharmaceutical network members fails to progress because cooperation with business partners does not proceed as planned, or if it is unable to acquire dispensing pharmacy stores through M&A as planned.」
Pharmaceutical network membership, pharmacy M&A and the off-balance-sheet treatment of multi-purpose facilities are identified as factors in achieving the plan.